Published in Women's Health Weekly, April 11th, 2002
Yasuji Yamamoto, from the Institute of Molecular and Cellular Biosciences at the University of Tokyo in Japan, said the compound, known as TAS-108, was being assessed in phase I clinical trials at the M.D. Anderson Cancer Center, Houston, Texas.
"We believe that TAS-108 is a promising antiestrogen for the treatment of breast cancer patients," said Dr. Tetsuji Asao,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly